Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease.
Cent Nerv Syst Agents Med Chem
; 24(1): 22-44, 2024.
Article
en En
| MEDLINE
| ID: mdl-38273763
ABSTRACT
Parkinson's disease (PD) is the second-most prevalent central nervous system (CNS) neurodegenerative condition. Over the past few decades, suppression of BCR-Abelson tyrosine kinase (c-Abl), which serves as a marker of -synuclein aggregation and oxidative stress, has shown promise as a potential therapy target in PD. c-Abl inhibition has the potential to provide neuroprotection against PD, as shown by experimental results and the first-in-human trial, which supports the strategy in bigger clinical trials. Furthermore, glutamate receptors have also been proposed as potential therapeutic targets for the treatment of PD since they facilitate and regulate synaptic neurotransmission throughout the basal ganglia motor system. It has been noticed that pharmacological manipulation of the receptors can change normal as well as abnormal neurotransmission in the Parkinsonian brain. The review study contributes to a comprehensive understanding of the approach toward the role of c-Abl and glutamate receptors in Parkinson's disease by highlighting the significance and urgent necessity to investigate new pharmacotherapeutic targets. The article covers an extensive insight into the concept of targeting, pathophysiology, and c-Abl interaction with α-synuclein, parkin, and cyclin-dependent kinase 5 (Cdk5). Furthermore, the concepts of Nmethyl- D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPA) receptor, and glutamate receptors are discussed briefly. Conclusion:
This review article focuses on in-depth literature findings supported by an evidence-based discussion on pre-clinical trials and clinical trials related to c-Abl and glutamate receptors that act as potential therapeutic targets for PD.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Proteínas Proto-Oncogénicas c-abl
/
Receptores de Glutamato
Tipo de estudio:
Qualitative_research
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cent Nerv Syst Agents Med Chem
Asunto de la revista:
FARMACOLOGIA
/
NEUROLOGIA
/
QUIMICA CLINICA
Año:
2024
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
Emiratos Árabes Unidos